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CHAPTER 1: INTRODUCTION 
1.1 Existence of T cells in human skin 
While there are many reports on T cells in human disease skin, skin T cells in stable 
healthy condition had been overseen for a long time. In 2006, Clark et al. reported that 
normal adult human skin contains around 20 billion T cells, twice as many as those in 
whole blood circulation, demonstrating that human skin is a large pool of T cells. The 
majority of skin T cells are αβ T cells and show memory phenotype [1]. Skin T cells are 
known to be distributed both in epidermis and dermis. In steady condition, most epidermal 
T cells stay in the epidermal basal layers along rete ridges while dermal T cells scatter 
below the epidermal-dermal junction or around blood vessels [2, 3].  
Memory T-cell population is constructed by differentiation of naïve T cells. Under 
appropriate TCR signals from MHC of APCs, naïve T cells are activated, then expand 
rapidly and most of them become effector T cells [4-6]. After the immune reaction is 
converged, many effector T cells undergo apoptosis while a small population survives and 
differentiates into memory T-cell subset. In addition to the classic memory T-cell subsets, 
central memory T cells (TCM) and effector memory T cells (TEM), in blood circulation [7], 
memory T cells have also been reported to stay in peripheral tissues such as skin [8]. 
Memory T cells in skin are known to express skin-addressing molecules CLA and CC-
chemokine receptor 4 (CCR4) and possess potent effector function [9] [2, 10]. Activation-
associated markers such as CD69, CD25 and HLA-DR were also expressed [11, 12]. 
1.2 Skin resident memory T cells in human 
From the observation of low-dose alemtuzumab treatment on leukemic cutaneous 
T-cell lymphoma (L-CTCL), it turned out that human skin contains both recirculating and 
sessile memory T cells. Alemtuzumab depletes CD52-expressing cells including T cells 
only in blood circulation. Skin of the patients treated with alemtuzumab lacks CCR7+L-
selectin+ memory T cells, which are the same phenotype as TCM in mice. This result 
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demonstrates that CCR7+L-selectin+ memory T cells in human skin behave as TCM and 
recirculate from skin. It is also proved that T cells remaining in skin after alemtuzumab 
treatment are skin-sessile and do not recirculate from skin [13]. These skin-sessile T cells 
are called resident memory T cells (TRM) and recognized by the surface markers CD69 and 
CD103 [14] (Fig. 1). CD69 is considered to contribute to retention of TRM in skin since 
CD69 is associated with downregulation G protein–coupled receptor for sphingosine 1 
phosphate (S1P1) [15]. S1P1-expressing T cells can egress from skin into lymph nodes and 
from lymph nodes into blood according to the gradients of S1P [16-18]. CD103 is an α 
chain of αEβ7 integrin and binds to E-cadherin, which is a homotypic adhesion molecule 
expressed in epithelial cells [19-21]. CD103 is reported to play an important role in 
longevity of TRM [14, 22] though the actual functional activity is yet to be known. TGF-β 
and IL-15 from keratinocytes and fibroblasts are reported to be necessary for the expression 
of TRM markers and long-term survival of TRM [23, 24]. CD49a, known as an α1 subunit of 
α1β1 integrin, is also reported to be a marker of TRM, especially epidermal CD8 TRM. 
CD49a attaches collagen IV, a component of the basement membrane between epidermis 
and dermis [25, 26]. It is of interest that CD49a expression in TRM is related to Tc1 
phenotype in human [27]. Additional studies showed the distinct cytokine production 
capacity of skin TRM [14, 28, 29], predisposing an evidence for the strong effector function 
of TRM. 
1.3 Resident memory T cells in human skin diseases 
The functions of skin T cells have been investigated mainly from the viewpoints of 
immune-mediated skin disorders and skin infectious diseases. As for immune-mediated 
skin disorders, TRM are reportedly involved in at least vitiligo, fixed drug eruption (FDE) 
and psoriasis. Vitiligo causes depigmented skin lesions where melanocytes are destructed 
through T-cell mediating cytotoxicity. Two independent reports on the phenotypes and 
functional profiles of TRM in vitiligo lesion demonstrate the production of 
proimflammatory cytokines such as IFN- and TNF- from CD8 TRM. CD49a+ TRM which 
possess IFN-γ-producing Tc1 profile are enriched in epidermis of vitiligo lesion [27, 30]. 
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In FDE, round annular erythematous plaques or bullas occur after systemic administration 
of certain drugs. The plaques remain as pigmented plaques and the erythema or bullas 
usually recur in the same sites after rechallenge of the same drugs [31]. Histologically, the 
presence of IFN-γ-producing CD8 T cells are found enriched in epidermis of clinically 
resolved FDE lesions [32]. These T cells in epidermis of resolved FDE express TRM 
markers CD69 and CD103 [33]. The antigen-specificity of these T cells has not yet been 
shown but it is supposed that these TRM in FDE exert reactivity against the drug-derived 
antigens. The roles of TRM in skin infectious disorders are also reported. In patients with 
genital HSV, CD8 TRM in dermal-epidermal junction of the previously HSV-infected 
sites are persistent and exert protective function [34]. The analyses of infectious diseases 
reveal that TRM survive for a long time in the absence of targeted antigens at the infected 
sites and provide a rapid immunologic response against the re-exposure of the same 
pathogens without recruiting other immune cells from the blood stream [35-37].  
1.4 Psoriasis 
Psoriasis is a chronic inflammatory skin disorder affecting 2-3% of worldwide 
population [38, 39]. Subtypes exist such as guttate psoriasis and generalized psoriasis but 
the most frequent phenotype is plaque-type psoriasis (psoriasis vulgaris), which makes up 
90% of all psoriasis cases [40]. Plaque-type psoriasis is characterized by well-demarcated, 
reddish and scaly plaques which typically persist or recur in the same sites (Fig. 2). Not 
limited to skin lesions, psoriasis is coming to be regarded as a systemic disorder and often 
accompanied by arthritis and metabolic disorders [41]. Increased risk of cardiovascular 
events possibly caused by chronic continuous inflammation should also be taken into 
account [42]. Even though psoriasis itself is not a lethal disease, the patients sometimes 
face severe social problems and the patients’ burden is reported to be as high as other 
chronic diseases such as diabetes and heart diseases [43]. It is thus complicated for 
dermatologists to evaluate the disease impact on each patient. In recent consensus, several 
indexes are used to define the severity of psoriasis. For instance, according to the Rule of 
Tens [44], the patient is regarded to be in severe condition if body surface area involved > 
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10 % or Psoriasis Area and Severity Index (PASI) score > 10 or Dermatology Life Quality 
Index (DLQI) score > 10. The treatment option ranges from skin-targeted treatments such 
as topical cream and ultraviolet therapies to systemic treatments such as immune-
suppressive medications and biologics. Dermatologists try to choose the suited treatment 
based on the severity of disease condition. However, it is difficult to decide when and how 
intensively the treatment should be started or modified. It is also controversial how to 
decrease the treatment intensity once the disease activity is controlled. 
1.5 Pathogenesis of psoriasis 
Some external factors such as infection, medications, trauma and stress and internal 
stimuli such as gene factors, autoantigens, immune cells and cytokines are reported to 
trigger psoriasis disease formation. Clinical reports indicated that a transplantation of bone 
marrow from a donor with psoriasis could result in development of psoriasis in the recipient 
without history of psoriasis [45]. This suggests that psoriasis derives from bone marrow 
cells. In a mouse model of human psoriasis where human non-lesional psoriatic skin was 
grafted to an immunodeficiency mouse strain, psoriatic lesion spontaneously developed in 
the grafted non-lesional skin. It is thus indicated that psoriatic disease formation can occur 
only by the cells existing in skin without recruitment of circulating cells [46]. In this 
xenograft model, neutralization of CD8 T cells by injecting anti-human CD8 antibodies 
prevented psoriatic disease formation in the non-lesional skin, demonstrating the 
importance of skin CD8 T cells in disease formation of psoriasis [47]. An efficacy of 
Cyclosporin A in psoriasis also confirmed the contribution of T cells in pathogenesis of 
psoriasis [48].  
Previously, IFN-γ-producing CD4 T cells (Th1 cells) were considered especially 
important because skin-resident IFN-γ-producing T cells have an ability to initiate psoriatic 
lesions [49, 50]. After discovery of Th17 cells [49-52], many reports demonstrated the role 
of IL-17A in the pathogenesis of psoriasis, leading to the establishment of psoriasis as Th17 
disease [51-58]. It is reported that IL-17A-producing CD4 T cells are distributed mainly in 
dermis and IL-17A-producing CD8 T cells are enriched in epidermis of psoriatic patients 
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[59-61]. The persistence of IL-17A-producing CD8 TRM is demonstrated even in resolved 
skin of psoriasis [62]. The relative production level of IL-17A to IFN-γ from T cells of this 
resolved skin inversely correlated with the duration of remission. However, the role of this 
CD8 TRM in disease initiation of psoriasis is still left unclear. 
 
CHAPTER 2: PURPOSE OF STUDY 
This study aims to elucidate the profiles of TRM from lesional and disease-naïve non-
lesional sites of psoriasis and investigate the involvement of TRM in psoriatic disease 
development. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Sample collection 
Human tissue samples were used in this study. All the protocols in this study were 
performed in accordance with the Declaration of Helsinki and were approved by the 
University of Tsukuba Hospital Institutional Review Board (Approval # H28-001). 
Informed consent was obtained from all the participants. 
Biopsy specimens were collected at University of Tsukuba Hospital from lesional 
and DN sites of 17 clinically and pathologically confirmed mild psoriasis patients (<10 
PASI score) who had only received topical and/or local ultraviolet treatments. Resolved 
sites were also excluded by thorough interview and examinations of the clinical 
manifestation. DN specimens were taken from the same anatomical sites as biopsied 
lesional sites and at least 5 cm apart from the lesion borders. Normal skin specimens from 
15 healthy donors were also collected from skin grafting procedures after resection of 
benign tumors, malignant in situ tumors (such as Bowen’s disease and basal cell 
carcinoma) or from the discarded edge of the resection of these tumors. The information 
of normal subjects is described in Table 1. These skin specimens were processed for either 
T-cell isolation or immunohistological evaluation. Due to sample size limitation, all 
experiments were not able to be conducted on each sample. The actual number of the 
samples analyzed in each experiment is indicated in each experimental method and figure 
legend. 
3.2 Flow cytometry 
T cells were isolated from lesional and DN sites of 12 psoriasis patients and 10 
normal skin specimens by two weeks of short-term explant culture as described previously 
[1] with Iscove's Modified Dulbecco's Media (IMDM) containing 10% Fetal Bovine Serum 
(FBS), penicillin/streptomycin and 2-Mercaptoethanol (2-ME) in the presence of 100 
IU/ml human recombinant IL-2 (Wako, Osaka, Japan) and 20 ng/ml human recombinant 
IL-15 (Wako). The following directly conjugated monoclonal antibodies for the indicated 
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molecules and isotype controls were used for surface or intracellular staining with optimal 
concentrations for flow cytometry analyses: human CD3 (SK7, Thermo Fisher Scientific, 
MA, USA), CD4 (RPA-T14, Thermo Fisher Scientific), CD8a (RPA-T8, Thermo Fisher 
Scientific), CD103 (Ber-ACT8, BioLegend) for cell-surface staining and IL-17A (BL168, 
BioLegend), IL-22 (22URTI, Thermo Fisher Scientific), IFN-γ (4S.B3, BioLegend) and 
TNF-α (MAb11, BioLegend) for intracellular staining. Prior to intracellular cytokine 
staining, cells were stimulated with Phorbol Myristate Acetate (PMA) (50 ng/ml, Wako) 
and ionomycin (0.5 µg/ml, Wako) plus Golgi Plug (BD Biosciences, CA, USA) for 4 hours. 
Cells were surface-stained, fixed, permeabilized and stained by anti-cytokine antibodies 
using BD Cytofix/Cytoperm Plus (BD Biosciences) according to the manufacturer’s 
protocol. Data collection was performed on a Beckman Coulter Gallios instrument 
(Beckman Coulter, IN, USA) and the data were analyzed by Kaluza Flow Analysis 
Software (Beckman Coulter). Lymphocyte population was determined by the intensity 
levels of forward scatter and side scatter. CD3 cells were determined by a histogram 
showing relative expression of CD3. CD4 T cells and CD8 T cells were further determined 
on the CD4 vs CD8 dot plot. Within these populations, the expression level of surface 
marker CD103 was analyzed. When cells were stimulated with PMA and ionomycin, CD3+ 
CD8- cells on the CD3 vs CD8 dot plot were regarded as CD4 T cells and cytokine 
expression was analyzed within this population. The gating strategies are shown in Fig. 3. 
3.3 Immunofluorescence analysis 
Formalin-fixed and paraffin-embedded specimens from lesional and DN sites of 5 
psoriasis patients and 5 normal donors were sliced into 3μm thickness on glass slides, de-
paraffinized and rehydrated. Antigen retrieval was performed using TE buffer (10x 
concentrate, pH 9.0, Agilent). After blocking, sliced specimens were incubated with 
indicated primary antibodies with the optimized concentrations for 60 min at room 
temperature. Primary antibodies used in this experiment were as follows: rabbit anti-human 
CD3 (ab5690, Abcam, Cambridge, UK), mouse anti-human CD8a (C8/144B, Agilent) and 
rabbit anti-human CD103 (EPR4166, Abcam). Secondary antibodies were applied after 
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rinsing the slides with the optimized concentrations for 60 min at room temperature. The 
following secondary antibodies were used: PE-conjugated donkey anti rabbit IgG antibody 
(ab150074, Abcam), FITC-conjugated goat anti mouse IgG antibody (ab150117, Abcam), 
PE-conjugated donkey anti mouse IgG antibody (ab150106, Abcam), and FITC-
conjugated goat anti rabbit IgG antibody (A-11034, Thermo Fisher Scientific). Finally, the 
cell nuclei were stained by  DAPI (Vector Laboratories, Burlingame, CA, USA), covered 
with coverslips and examined by KEYENCE fluorescence microscope BZ-X700 
(Keyence, Osaka, Japan).  
3.4 Statistical analysis 
Data were expressed as mean ± standard deviation. Comparison among three groups 
was performed by one-way ANOVA. Paired t-test was used for comparison between two 
groups. Linear regression test was applied for comparison between cytokine expression 
and disease duration. P value of < 0.05 was taken as statistically significant unless 
mentioned separately. 
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CHAPTER 4: RESULTS 
4.1 CD8 TRM with CD103 expression are enriched both in lesional and disease-naïve 
non-lesional sites of psoriasis skin  
Isolated T cells from two-week expansion culture of psoriatic and normal skin were 
analyzed for surface molecules by flow cytometry. Psoriatic lesional and DN sites showed 
a slight tendency of CD8 T-cell enrichment compared to normal skin though the difference 
did not reach significance (Fig. 4A, lesion vs DN: p>0.9999, lesion vs normal: p>0.9999, 
DN vs normal: p>0.9999, Table 2). Interestingly, among the CD8 T cell population, 
lesional and DN skin from psoriasis patients included significantly more CD103+ cells 
(CD103+ CD8 TRM) than normal skin (Fig. 4B, lesion vs DN: p>0.9999, lesion vs normal: 
p=0.0058, DN vs normal: p=0.0181, Table 3). Meanwhile, the percentage of CD103+ TRM 
in CD4 fraction was lower in lesional sites of psoriatic patients compared to normal (Fig. 
4B, lesion vs DN: p= 0.0942, lesion vs normal: p<0.0007, DN vs normal: p=0.3082). These 
results demonstrate that T-cell profiles in normal-looking psoriatic DN sites are already 
skewed and enriched with CD103+ CD8 TRM. 
4.2 CD103+ CD8 TRM are dominated in epidermis of both lesional and disease-naïve 
non-lesional sites of psoriasis skin 
In order to determine the localization of CD8 T cells, especially CD103+ CD8 TRM  
in skin, first, the number of CD8 T cells in epidermis and dermis were counted from 100 
µm in width of the specimens of lesional and DN sites of psoriasis patients and normal 
skin. Then lesional skin contained more CD8 T cells compared to normal skin, especially 
in epidermis. DN skin, especially epidermis, also included significantly more CD8 T cells 
compared to normal skin (Fig. 5A, B, in whole skin, lesion vs DN: p=0.0001, lesion vs 
normal: p<0.0001, DN vs normal: p=0.0255; in epidermis, lesion vs DN: p=0.0024, lesion 
vs normal: p<0.0001, DN vs normal: p=0.0259; in dermis, lesion vs DN: p<0.0001, lesion 
vs normal: p<0.0001, DN vs normal: p=0.0670, Table 3). Within each sectioned specimen, 
CD8 T cells localized more in epidermis than in dermis both in lesional and DN sites (Fig. 
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5C, lesion: p=0.0213; DN: p=0.0170; normal: p=0.0516, Table 4). These results are in 
concordance with the flow cytometry results and it is indicated that even DN sites from 
psoriasis patients contain more CD8 T cells especially in epidermis compared to normal 
skin. 
As for TRM fractions, the CD103+ CD8 TRM population was significantly dominant 
in epidermis compared to dermis among psoriasis skin including lesional and DN sites and 
normal skin (Fig. 6A, B, lesion: p=0.0093; DN: p=0.0349; normal: p=0.0367, Table 5). 
Among the three groups, within epidermis, both lesional and DN skin contained 
significantly more CD103+ CD8 TRM compared to normal skin (Fig. 6C, lesion vs DN: 
p=0.0119, lesion vs normal: p<0.0001, DN vs normal: p=0.0297, Table 5). On the other 
hand, in dermis, CD103+ CD8 TRM numbers were low and only slightly high in lesional 
skin (Fig. 6C, lesion vs DN: p=0.1953, lesion vs normal: p=0.0102, DN vs normal: 
p=0.2420, Table 5). These results show that CD103+ CD8 TRM, are enriched and localized 
mainly in epidermis of both lesional and DN skin of psoriasis. 
4.3 CD8 T cells in disease-naïve non-lesional sites of psoriasis skin have IL-17A-
generating potential 
Cytokine production profiles of skin T cells isolated by short-term expansion culture 
were compared by flow cytometry analysis after stimulation with PMA and ionomycin. 
The ratios of IL-22, TNF-α- or IFN-γ-producing cells in CD4 and CD8 fractions were 
comparable among the three groups (Fig. 7A, B, IL-22 in CD4; lesion vs DN: p>0.9999, 
lesion vs normal: p>0.9999, DN vs normal: p>0.9999; IFN-γ in CD4; lesion vs DN: 
p>0.9999, lesion vs normal: p>0.9999, DN vs normal: p>0.9999; TNF-α in CD4; lesion vs 
DN: p=0.6966, lesion vs normal: p>0.9999, DN vs normal: p=0.2990; IL-22 in CD8; lesion 
vs DN: p=0.7636, lesion vs normal: p>0.9999, DN vs normal: p=0.2163; IFN-γ in CD8; 
lesion vs DN: p>0.9999, lesion vs normal: p>0.9999, DN vs normal: p>0.9999; TNF-α in 
CD8; lesion vs DN: p>0.9999, lesion vs normal: p>0.9999, DN vs normal: p>0.9999, Table 
6). Notably, within the CD8 T cell population, a significantly increased ratio of IL-17A 
production was observed in both lesional and DN skin compared to normal skin (Fig. 7A, 
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B: lesion vs DN: p>0.9999, lesion vs normal: p=0.0007, DN vs normal: p=0.0012, Table 
6). As for the CD4 T cell fraction, IL-17A production was comparable among three groups 
(Fig. 7A, B, lesion vs DN: p>0.9999, lesion vs normal: p>0.9999, DN vs normal: p>0.9999, 
Table 6). From these results, DN sites of psoriasis also include IL-17A-producing CD8 T 
cells even before disease manifestation.  
4.4 CD103+ CD8 TRM from disease-naïve non-lesional sites of psoriasis possess a 
potent IL-17A-producing phenotype 
When cytokine production capacity of CD103+ CD8 TRM were further compared, 
significantly more IL-17A-producing CD103+ CD8 TRM were detected both in psoriatic 
lesional and DN skin than normal skin (Fig. 8, lesion vs DN: p>0.9999, lesion vs normal: 
p=0.0006, DN vs normal: p=0.0020, Table 7). The production of IL-22, IFN-γ and TNF-α 
was not increased in psoriatic skin (Fig. 8, IL-22: lesion vs DN: p=0.7262, lesion vs normal: 
p>0.9999, DN vs normal: p=0.3126. IFN-γ: lesion vs DN: p>0.9999, lesion vs normal: 
p>0.9999, DN vs normal: p=0.8798. TNF-α: lesion vs DN: p>0.9999, lesion vs normal: 
p>0.9999, DN vs normal: p>0.9999, Table 7). The production profiles of these cytokines 
in CD103- CD8 T cells also showed a similar tendency with significantly higher IL-17A 
production ratio in both psoriatic lesional and DN sites than in normal skin (Fig. 8, IL-17A: 
lesion vs DN: p>0.9999, lesion vs normal: p=0.0053, DN vs normal: p=0.0005. IL-22: 
lesion vs DN: p>0.9999, lesion vs normal: p>0.9999, DN vs normal: p=0.8726. IFN-γ: 
lesion vs DN: p>0.9999, lesion vs normal: p>0.9999, DN vs normal: p>0.9999. TNF-α: 
lesion vs DN: p>0.9999, lesion vs normal: p>0.9999, DN vs normal: p>0.9999, Table 7). 
The production ratios of IL-17A and IL-22 in CD103+ CD8 TRM cells were higher than in 
CD103- CD8 T cells in psoriatic lesional and DN sites. Of note, IL-17A production ratio 
was far higher in CD103+ CD8 TRM cells than in CD103- CD8 T cells. IFN-γ and TNF-α 
production levels showed a similar tendency among these population (Figure 8A, IL-17A: 
p=0.0005 in lesion, p=0.0010 in DN, p=0.1250 in normal; IL-22: p=0.0059 in lesion, 
p=0.0391 in DN, p=0.1250 in normal; IFN-γ: p=0.2661 in lesion, p=0.0342 in DN, 
p=0.6406 in normal; TNF-α: p=0.1475 in lesion, p=0.6523 in DN, p=0.9375 in normal, 
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Table 7). CD103+ CD8 TRM both in psoriatic lesional and DN sites thus serve as a 
responsible source of IL-17A.  
4.5 Relative expression levels of IL-17A to IFN-γ in CD103+ CD8 TRM from disease-
naïve non-lesional sites correlate with disease duration 
 In our study, we used PASI score to evaluate disease severity. However, PASI score 
did not correlate with disease duration (Fig. 9A). Correlation between PASI score or 
disease duration and CD103+ CD4 TRM or CD103+ CD8 TRM both in psoriatic lesional and 
DN sites was not observed, either (Fig. 9B, C).  In addition, from aspect of cytokines, we 
found that the ratio of IL-17A-producing cells in whole CD8 fraction in DN sites tended to 
be higher in the patients with longer disease duration (Fig. 10A, p=0.0813) although the 
tendency did not show significant difference. However, the ratio of % IL-17A-producing 
cells to % IFN-γ-producing cells in whole CD8 in DN sites correlated with disease duration 
(Fig. 10B, p=0.0270). Within CD8 T cells, %IL-17A/% IFN-γ-producing cells correlated 
with disease duration in CD103+ CD8 TRM but not in CD103- CD8 fraction (Fig. 10B, 
p=0.0343 in CD103+CD8 TRM, p=0.1119 in CD103-CD8). 
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CHAPTER 5: DISCUSSION 
In addition to previous reports showing IL-17A production from CD8 TRM in 
lesional and resolved sites [60, 62], our results demonstrate that CD103+ CD8 TRM residing 
in psoriatic DN sites already possess IL-17A-generating potential. These cells are confined 
in epidermis. On the other hand, the production levels of IL-17A in CD103- CD8 T cells 
are much lower than those in CD103+ CD8 TRM. These results may implicate the role of 
CD103+ CD8 TRM within DN sites in the pathogenesis of psoriasis. Recent studies 
suggested the relationship of cells resident in skin to the pathogenesis of psoriasis as the 
grafted psoriatic non-lesional skin in an immunodeficient mouse strain spontaneously 
developed psoriatic lesion without grafting any human circulating cells [63]. Other 
experiments demonstrated that the blockage of E-selectin, which plugs the trafficking of 
memory T cells into skin from blood, is not effective in the treatment of psoriasis even 
though its importance in psoriatic pathogenesis was previously suggested [64, 65]. Based 
on these reports, psoriatic disease formation does not apparently require recruitment of 
cells from circulation [66, 67].  
Psoriasis is regarded as an IL-17-mediated disorder [68-70] as both active and 
resolved psoriatic lesions contain CD4 and CD8 T cells that produce IL-17 and IL-22 [62, 
71]. Notably, CD8 T cells from DN sites also showed a higher IL-17A production profile 
than those from normal skin. Furthermore, among these CD8 T cells, epidermal CD103+ 
CD8 TRM cells in both psoriatic lesional and DN sites demonstrated a significantly higher 
IL-17A-generating potential compared to normal skin. On the other hand, IL-17A-
producing potential was far higher in CD103+ CD8 TRM cells than in CD103- CD8 T cells, 
even though CD103- CD8 T cells from psoriatic lesional and DN sites also showed 
significantly more IL-17A production than normal skin.  
From the aspect of clinical manifestation, our results demonstrate that the 
production ratio of IL-17A to IFN-γ increases along with disease duration in whole CD8 
and CD103+ CD8 TRM fraction, but not in CD103- CD8 T-cell fraction, residing in psoriatic 
DN, suggesting that the relative accumulation of IL-17A-generating TRM in DN according 
20 
 
to chronic disease activity makes the prepared condition for disease formation. This result 
aligns with the negative correlation of IL-17A/IFN-γ and IL-17A/IL-10 ratios in the 
resolved psoriatic skin with the duration of remission [72]. Relative accumulation of IL-
17A-producing cells will thus make the foundation for further lesion development. CD4 T 
cells have been indicated in many reports to serve as a source of IL-17A in the pathogenesis 
of psoriasis. Our observation corresponds with the previous indication that CD4 T cells 
maintain psoriatic lesions [73-75] and may also support the idea that IL-17A-producing 
CD8 TRM cells are involved in disease staging and pathogenesis [47]. We were limited in 
observations of this development as we were not able to follow up to see if the biopsied 
non-lesional sites actually develop psoriatic disease. At least since these sites are not 
developing psoriatic lesions at the time of biopsy even with plenty amount of IL-17A-
producing CD8 TRM, other factors would be needed for disease formation. Investigating the 
direct factors for lesion initiation would be required for revealing the detailed contribution 
of this fraction to disease pathogenesis. 
In clinical settings, some patients experience unexpectedly long remission periods 
after intermitting treatments including biologics. Clinical trials of 2 distinct biologics 
demonstrated that 5 to 10 % of the participants maintain the remission status with over 
75 % of PASI improvement [76-78]. These results raise the argument on intermission of 
biologics and on the evaluation of deep remission. Evaluating IL-17A profiles of TRM in 
DN may have a potentiality of serving as an index not only for future disease manifestation 
but also for required treatment intensity from the viewpoint of treatment modality and 
treatment duration. 
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CHAPTER 6: OVERVIEW AND PROSPECTS 
Psoriasis is a chronic inflammatory skin disease which is characterized by 
hyperproliferation of keratinocytes and infiltration of immune competent cells. After 
discovery of Th17 cells, many reports demonstrated the role of IL-17A-producing T cells 
in the pathogenesis of psoriasis, leading to its establishment as an IL-17-mediated disease. 
From clinical aspects, psoriatic lesion is well-demarcated and recurs in the same sites, 
suggesting that disease formation is mediated by skin-sessile cells. However, the detailed 
roles of TRM in the pathogenesis of psoriasis are still left unclear. 
In this study, we found a dominance of CD103+ CD8 TRM in psoriatic DN sites, 
which have never experienced disease formation. Thus, normal-looking sites in psoriasis 
patients already have skewed distribution of T cells before disease manifestation. Previous 
reports showed both active and resolved psoriatic lesions contain CD4 and CD8 T cells 
with a potential of producing IL-17A. Keratinocytes of DN sites were also reported to 
upregulate CCL20 expression, which recruit CCR6+ IL-17A-producing T cells. In this 
research, we demonstrated the IL-17A-generating phenotype of CD8 T cells in psoriatic 
DN sites. Meanwhile, in CD4 fraction, IL-17A-producing potential was comparable among 
lesion, DN and normal skin. It is assumed that CD8 T cells are strikingly involved in 
preparation and initiation of disease formation. In comparison with CD103- CD8 T cells, 
CD103+ CD8 TRM demonstrated a significantly stronger ability of IL-17A production in 
both lesional and DN sites. These results implicate a contribution of CD103+ CD8 TRM to 
the pathogenesis of lesion formation in DN sites. 
We revealed that IL-17A-producing CD8 TRM are accumulated in epidermis of 
psoriatic DN sites according to disease course. IL-17A-producing CD103+ CD8 TRM may 
be considered not only as an index for baseline disease activity but also as a predictor of 
suited treatment intensity. In addition, IL-17A-producing CD8 TRM may also be an 
attractive treatment target for preventing disease progress. On the other hand, since these 
DN sites do not immediately develop psoriatic lesions even in the presence of IL-17A-
22 
 
producing CD8 TRM, finding other factors eliciting disease formation cascade will be of 
great importance in the treatment strategy of psoriasis. 
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FIGURES AND LEGENDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Memory T cell subsets were found in skin. Upon the appropriate 
interaction of the signals, naïve T cells are activated by antigen presenting cells. Then, 
memory T cells fractions are constructed from the naïve T cells. TCM expressing CCR7 
and L-selectin are circulating between blood stream, skin and lymph nodes. TEM are 
found both in blood stream and skin. After migrating into skin, a certain subset of 
memory T cells is regarded to be differentiated into TRM and stay in skin for a long 
time even in the absence of antigens and provide a rapid response against the re-
exposure of the same pathogens without recruiting the cells from the circulation. Ag: 
antigen, APC: Antigen Presenting Cell, MHC: Major Histocompatibility Complex, 
TCM: central memory T cells, TCR: T- Cell Receptor, TEM: effector memory T cells, 
TRM: resident memory T cells. 
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Figure 2: Clinical manifestation of plaque-type psoriasis. Courtesy of Dr. Rei 
Watanabe. The lesion of psoriasis is a well-demarcated, raised, red plaque with 
a white scaly surface. The new psoriatic lesions recur on pigmented plaques 
where are the previous psoriatic lesions (on the right picture). 
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Figure 3: Gating strategy. Lymphocyte were gated by the intensity levels of 
forward scatter (FS) and side scatter (SS). Then, CD3 T cells were determined by a 
histogram indicating relative expression of CD3. (A) In cell surface gating, without 
stimulation, CD4 T cells and CD8 T cells were performed on the CD4 vs CD8 dot 
plot. Within these populations, the expression level of surface marker CD103 was 
further analyzed. (B) In cytokine gating, after stimulating the cells with PMA and 
ionomycin, CD3+ CD8- cells on the CD3 vs CD8 dot plot were regarded as CD4 T 
cells. Then, the expression level of surface marker CD103 was analyzed. Next, 
cytokine production was analyzed in these populations. The demonstration of 
analyzing IL-17 and IL-22 in CD8, CD103+ CD8 TRM was example for gating 
cytokines.  
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Figure 4: Both lesional and disease-naïve non-lesional sites from psoriasis 
patients are enriched with CD103+ CD8 TRM cells. T cells were harvested from 
12 psoriasis patients at both lesional and DN sites as well as skin from 10 normal 
subjects after two weeks of explant culture, then analyzed by flow cytometry. (A) 
Representative flow cytometry dot plots of CD4 and CD8 populations and a 
cumulative graph showing CD4/CD8 ratio from lesional and DN sites of psoriasis 
patients and normal skin specimens. (B) Representative flow cytometry 
histograms of CD103 expression in CD4 and CD8 T cells and cumulative graphs 
from lesional and DN sites of the same psoriasis patient and a normal control 
showing the percentage of CD103+ (CD103+ TRM) in CD4 and CD8 fractions. L: 
lesion; DN: disease-naïve non-lesion. *p < 0.05, **p < 0.01, ***p < 0.001. Error 
bar: mean ± SD. 
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Figure 5: CD8 T cells are predominantly localized to epidermis of lesional 
psoriatic skin. (A) Immunofluorescence staining of CD3 (red) and CD8 (green) 
expression was performed on formalin-fixed, paraffin-embedded skin specimens in 
lesional psoriatic skin. (B) The actual number of CD8 T cells was counted in whole 
skin, epidermis and dermis from psoriatic lesional and DN sites, and normal skin 
specimens. (C) A comparison of CD8 T-cell numbers in epidermis and dermis of 
the same individuals from the stained sections in (A). Cell counts within 100 µm of 
epidermis and dermis of the stained sections in (A). Five cases are included in each 
group. L: lesion; DN: disease-naïve non-lesion. Epi: Epidermis. Derm: Dermis. 
Scale bar = 100 µm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001. Error bar: 
mean ± SD. 
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Figure 6: CD103+ CD8 TRM cells predominately localize in epidermis of both 
lesional and DN psoriatic skin. (A) Immunofluorescence staining of CD8 (red) and 
CD103 (green) expression was performed on formalin-fixed, paraffin-embedded skin 
in lesional and DN sites from psoriasis patients and in normal skin. (B) The number 
of CD103+ CD8 TRM in epidermis and dermis of the same individuals from psoriatic 
lesional and DN specimens and normal skin were compared from 100 µm widths of 
the stained specimens. The same sections as in (A) were used. (C) Number of CD103+ 
CD8 TRM cells in epidermis and dermis were compared among lesional and DN sites 
of psoriatic and normal skin specimens. Cells were counted within a 100 µm of 
epidermis and dermis from the stained sections in (A). Five cases are included in each 
group. L: psoriasis lesion; DN: disease-naïve non-lesion. Scale bar = 100 µm. *p < 
0.05, **p < 0.01, ****p<0.0001. Error bar: mean ± SD. 
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Figure 7: CD8 T cells with IL-17A-generating potential are enriched both in 
psoriatic lesional and DN skin. (A) Representative flow cytometry dot plots 
showing the profiles of IL-17A, IL-22, IFN-γ and TNF-α production from CD4 and 
CD8 fractions of psoriatic lesional and DN skin from the same patients as well as 
normal skin. Isolated T cells from two weeks of explant culture were stimulated with 
PMA and ionomycin for four hours and then stained for surface markers and 
intracellular cytokines. (B) Cumulative graphs showing production of each cytokine 
in CD4 and CD8 T cells. A total of 12 L, 12 DN and 10 Normal were analyzed for 
IL-17A. 10 L, 10 DN and 5 Normal for IL-22, 12 L, 12 DN and 8 Normal for IFN-
γ and 11 L, 9 DN and 7 Normal for TNF-α. L: lesion; DN: disease-naïve non-lesion. 
*p < 0.05, **p < 0.01. Error bar: mean ± SD. 
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Figure 8: CD103+ CD8 TRM cells from psoriatic disease-naïve, non-lesional 
skin have an IL-17A-generating potential. The cells were harvested after 2 
weeks of explant culture, and then stimulated with PMA and ionomycin for four 
hours before cell-staining and analysis by flow cytometry. The percentage of the 
cells producing the indicated cytokines in CD103+ CD8 TRM (upper panels) and 
CD103- CD8 T cells (lower panels). 12 L, 12 DN and 10 Normal were analyzed 
for IL-17A, 10 L, 10 DN and 5 Normal for IL-22, 12 L, 12 DN and 8 Normal for 
IFN-γ and 11 L, 9 DN and 7 Normal for TNF-α. L: lesion; DN: disease-naïve non-
lesion. **p < 0.01, ***p < 0.001. Error bar: mean ± SD. 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9A, B: No correlation between PASI score or disease duration and 
CD103+ CD4 TRM or CD103+ CD8 TRM. (A) PASI score did not correlate with 
disease duration (top left). (B) The middle panels showed no correlation between 
PASI score or disease duration and CD103+ CD4 TRM in psoriatic lesional skin. 
In addition, correlation between PASI score or disease duration and CD103+ CD4 
TRM in DN sites was not observed (the lower panels). L: lesion; DN: disease-naïve 
non-lesion. N=12. 
 
A 
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Figure 9C: No correlation between PASI score or disease duration and CD103+ 
CD4 TRM or CD103+ CD8 TRM. (C) The upper panels showed no correlation 
between PASI score or disease duration and CD103+ CD8 TRM in psoriatic lesional 
skin. In addition, correlation between PASI score or disease duration and CD103+ 
CD8 TRM in DN sites was not observed (the lower panels). L: lesion; DN: disease-
naïve non-lesion. N=12. 
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Figure 10: The ratio of IL-17A/IFN- in CD103+ CD8 TRM was correlated with 
disease duration. (A) Top left: The relation of disease duration and %IL-17A 
production in whole CD8 T cells from DN. (B) Top right: The ratio of %IL-17A-
producing cells/%IFN-γ-producing cells in whole CD8 T cells from DN. In CD8 T 
cells, this IL-17A/IFN-γ production ratio in CD103+ CD8 TRM (left) and CD103- 
CD8 T cells (right) from DN sites of 12 psoriasis patients are shown according to 
disease duration. 
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TABLES 
Table 1: Description of the normal subjects 
Normal 
Age Gender 
84 M 
49 F 
68 M 
72 M 
66 F 
72 M 
56 M 
87 F 
64 F 
96 F 
72 F 
57 F 
54 M 
37 M 
79 M 
 
Table 2: The ratio of CD4/CD8 T cells in psoriatic lesional, DN sites and normal skin  
Skin specimens The ratio of CD4/CD8 T cells (Mean ± SD) 
Lesional skin 2.3 ± 1.7 
DN skin 1.9 ± 1.2 
Normal skin 3.1 ± 2.5 
 
 Table 3: Comparative data of the expression of CD103+ TRM in CD4 and CD8 T cells 
 Percentage of CD103+ in difference groups (Mean ± SD) 
 In CD4 T cells In CD8 T Cells 
Lesional skin 14.4 ± 7.8 47.8 ± 10.8 
DN skin 25.9 ± 12.7 50.8 ± 19.1 
Normal skin 35.8 ± 12.4 28.3 ± 11.2 
 
Table 4: CD8 T cells counted within 100 µm from immunofluorescence-stained pictures  
Skin 
specimens 
Number of CD8 T cells in different groups (Mean ± SD) 
Whole skin Epidermis Dermis 
Lesional skin 52.2 ± 13.4 34.2 ± 12.1 18.0± 4.4 
DN skin 20.4 ± 3.4 15.6 ± 2.3 4.8 ± 1.3 
Normal skin 5.0 ± 1.2 3.2 ± 0.8 1.8 ± 0.8 
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Table 5: CD103+ CD8 TRM cells counted within 100 µm from immunofluorescence-
stained pictures  
Skin 
specimens 
Number of CD103+ CD8 TRM cells in 
different groups (Mean ± SD) 
Epidermis Dermis 
Lesional skin 18.0 ± 5.2 6.0 ± 3.1 
DN skin 9.8 ± 3.7 3.4 ± 2.1 
Normal skin 2.8 ± 0.8 1.0 ± 1.0 
 
Table 6: Comparative data of IL-17A, IL-22, TNF-α, and IFN-γ-producing cells in CD4 
and CD8 fractions 
 
 
Skin 
specimens 
Percentage of CD4 or CD8 in difference groups (Mean ± SD) 
IL-17A IL-22 IFN-γ TNF-α 
CD4 
cells 
CD8 
cells 
CD4 
cells 
CD8 
cells 
CD4 
cells 
CD8 
cells 
CD4 
cells 
CD8 
cells 
Lesional 
skin 
11.0 ± 
12.3 
11.9 ± 
8.8 
10.7 ± 
10.2 
7.4 ± 
7.5 
21.9 ± 
16.0 
48.5 ± 
25.9 
68.3 ± 
24.2 
80.0 ± 
19.0 
DN skin 
10.7 ± 
10.6 
11.9 ± 
9.3 
14.0 ± 
11.8 
10.2 ± 
6.2 
20.1 ± 
12.0 
49.2 ± 
30.1 
77.6 ± 
22.2 
83.3 ± 
12.6 
Normal skin 
8.4 ± 
7.4 
0.5 ± 
0.8 
11.6 ± 
6.0 
3.6 ± 
2.9 
22.9 ± 
11.0 
44.9 ± 
19.4 
66.2 ± 
20.0 
84.3 ± 
6.9 
 
Table 7: Percentage of cytokine production capacity of CD103+ CD8 TRM and CD103- 
CD8 T cells (Mean ± SD) 
 
Skin 
specimens 
IL-17A IL-22 IFN-γ TNF-α 
In CD103+ 
CD8 TRM 
Lesional skin 18.6 ± 12.3 10.5 ± 10.5 50.0 ± 26.0 81.2 ± 19.3 
DN skin 17.5 ± 14.1 13.3 ± 7.8 54.5± 30 83.3 ± 11.3 
Normal skin 0.9 ± 1.9 5.3 ± 3.7 45.9 ± 17.3 83.6 ± 6.6 
In CD103- 
CD8 T cells 
Lesional skin 2.7 ± 2.5 3.7 ± 3.7 44.1 ± 27.2 76.0 ± 20.0 
DN skin 5.3 ± 6.3 6.1 ± 8.5 43.0 ± 32.2 81.1 ± 16.5 
Normal skin 0.05 ± 0.1 1.8 ± 1.8 43.1 ± 22.6 83.7 ± 9.2 
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